Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV002227698 | SCV002506779 | uncertain significance | Nicolaides-Baraitser syndrome; Blepharophimosis-impaired intellectual development syndrome | 2021-07-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003093900 | SCV003529789 | uncertain significance | Inborn genetic diseases | 2021-06-02 | criteria provided, single submitter | clinical testing | The c.632C>T (p.T211M) alteration is located in exon 4 (coding exon 3) of the SMARCA2 gene. This alteration results from a C to T substitution at nucleotide position 632, causing the threonine (T) at amino acid position 211 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |